Study S001029

Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06935838
Study type: INTERVENTIONAL
Phase: PHASE2
Masking: NONE
Status: COMPLETED
Enrollment: 12
Start: 2025-11-12
Primary completion: 2026-06-02
Lead sponsor: University of Hawaii
Conditions: Obesity and Overweight; HIV; Chronic Inflammation
Interventions: DRUG:Tirzepatide
Results posted: FALSE
Secondary identifiers: NIH:U54GM138062

Registered primary outcomes

Change in Baseline Body Weight [12 weeks]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0001746	Glucagon-like Peptide 1 Receptor Agonists Promote Weight Loss Among People With HIV. Nguyen Q, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America	2024	Nonrandomized study	PMID 38501237 DOI	registry reference BACKGROUND:38501237
R0010987	Tirzepatide Once Weekly for the Treatment of Obesity. Jastreboff AM, The New England journal of medicine	2022	Randomized trial	PMID 35658024 DOI	registry reference BACKGROUND:35658024